MYDA Advisors’s Creative Medical Technology CELZ Stock Holding History

MYDA Advisors’s Portfolio CELZ Stock Details CELZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.21M	Buy	+4,500,000	New	+$4.49M	0.47%	57

Other funds holding CELZ

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Global Retirement Partners San Rafael, California $7.1B AUM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.75B AUM 16.25% 1-Year Est. Return

MYDA Advisors's CELZ Position: Q3 2026 in Review

MYDA Advisors opened a new position in Creative Medical Technology (CELZ) in Q3 2026: 4,500,000 shares worth $4.21M. The stake represents 0.47% of the portfolio and ranks #57 among its holdings.

15 funds tracked by Wall St. Rank hold CELZ as of Q3 2026.

MYDA Advisors held 4,500,000 shares of Creative Medical Technology worth $4.21M as of Q3 2026.
Creative Medical Technology was a new MYDA Advisors position in Q3 2026.
Creative Medical Technology made up 0.47% of MYDA Advisors's portfolio in Q3 2026, its #57 holding.
15 funds tracked by Wall St. Rank held Creative Medical Technology as of Q3 2026.

Based on MYDA Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.